9 research outputs found
The use of intranasal glucocorticosteroids in the treatment of rhinosinusitis: Focus on mometasone furoate [Intranazal'nye glyukokortikosteroidy v terapii rinosinusita: fokus naΒ mometazona furoat]
Π ΡΡΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΈΠ½ΡΡΠ°Π½Π°Π·Π°Π»ΡΠ½ΡΡ
Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² (ΠΈΠ½ΠΠΠ‘) ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ, ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΡΡΡΠ΅ΠΌ ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΈΠ½ΠΎΡΠΈΠ½ΡΡΠΈΡΠ΅ (Π Π‘). Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅ΠΉ Π²Π΅ΡΡΠΈΠΈ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ ΠΈΠ½ΠΠΠ‘ ΠΏΡΠΈΡΠ²ΠΎΠ΅Π½ Π²ΡΡΡΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡΡΠ² β Ia ΠΈ Π²ΡΡΡΠ°Ρ ΡΠΈΠ»Π° ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ β Π ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ Π Π‘ ΠΈ ΠΏΠΎΠ»ΠΈΠΏΠΎΠ·Π½ΠΎΠΌ Π Π‘. ΠΠ½ΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ°ΡΡ ΡΡΠ°ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π Π‘ Π±Π΅Π· ΠΏΠΎΠ»ΠΈΠΏΠΎΠ². Π ΡΠΈΡΠ»Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Ρ
ΠΎΡΠΎΡΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΌΠΎΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΡΡΠΎΠ°Ρ, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠΉ ΠΏΡΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌΠΈ. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π² Π Π€ Π² 2015 Π³. Π½ΠΎΠ²ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΌΠΎΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΡΡΠΎΠ°ΡΠ° Π² ΡΠΎΡΠΌΠ΅ ΠΈΠ½ΡΡΠ°Π½Π°Π·Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΡΠ΅Ρ ΠΠ΅Π·ΡΠΈΠ½ΠΈΡ (ΠΠΠ Β«Π’Π΅Π²Π°Β») Π² ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ (Π ΠΠ) ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π» ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΠ°Π·ΠΎΠ½Π΅ΠΊΡ.The authors discuss the mechanism of action, effectiveness, and safety of intranasal glucocorticosteroids (inGCS) used to treat acute, recurrent and chronic rhinosinusitis (RS). The last version of the European guidelines concerning the application of inGCS assigns the highest level of evidence-Ia and the highest strength of recommendations-A to these medications when applied for the treatment of acute and polypoid rhinosinusitis. Moreover, they acquire the status of the agents of choice for the therapy of chronic RS without polyps. Mometasone furoate is one of the best explored preparations of this group of medicines. It is possessed of favourable pharmacodynamic and pharmacokinetic properties when prescribed for local application. The new mometasone furoate preparation in the form of an intranasal spray Dezrinit produced by "Teva" Ltd. was registered in the Russian Federation. In a comparative randomized clinical trial (RCT), the preparation was shown to be an equivalent to the Nasonex spray
The use of intranasal glucocorticosteroids in the treatment of rhinosinusitis: Focus on mometasone furoate [Intranazal'nye glyukokortikosteroidy v terapii rinosinusita: fokus naΒ mometazona furoat]
Π ΡΡΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΈΠ½ΡΡΠ°Π½Π°Π·Π°Π»ΡΠ½ΡΡ
Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² (ΠΈΠ½ΠΠΠ‘) ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ, ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΡΡΡΠ΅ΠΌ ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΈΠ½ΠΎΡΠΈΠ½ΡΡΠΈΡΠ΅ (Π Π‘). Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅ΠΉ Π²Π΅ΡΡΠΈΠΈ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ ΠΈΠ½ΠΠΠ‘ ΠΏΡΠΈΡΠ²ΠΎΠ΅Π½ Π²ΡΡΡΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡΡΠ² β Ia ΠΈ Π²ΡΡΡΠ°Ρ ΡΠΈΠ»Π° ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ β Π ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ Π Π‘ ΠΈ ΠΏΠΎΠ»ΠΈΠΏΠΎΠ·Π½ΠΎΠΌ Π Π‘. ΠΠ½ΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ°ΡΡ ΡΡΠ°ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π Π‘ Π±Π΅Π· ΠΏΠΎΠ»ΠΈΠΏΠΎΠ². Π ΡΠΈΡΠ»Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Ρ
ΠΎΡΠΎΡΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΌΠΎΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΡΡΠΎΠ°Ρ, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠΉ ΠΏΡΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌΠΈ. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π² Π Π€ Π² 2015 Π³. Π½ΠΎΠ²ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΌΠΎΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΡΡΠΎΠ°ΡΠ° Π² ΡΠΎΡΠΌΠ΅ ΠΈΠ½ΡΡΠ°Π½Π°Π·Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΡΠ΅Ρ ΠΠ΅Π·ΡΠΈΠ½ΠΈΡ (ΠΠΠ Β«Π’Π΅Π²Π°Β») Π² ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ (Π ΠΠ) ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π» ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΠ°Π·ΠΎΠ½Π΅ΠΊΡ.The authors discuss the mechanism of action, effectiveness, and safety of intranasal glucocorticosteroids (inGCS) used to treat acute, recurrent and chronic rhinosinusitis (RS). The last version of the European guidelines concerning the application of inGCS assigns the highest level of evidence-Ia and the highest strength of recommendations-A to these medications when applied for the treatment of acute and polypoid rhinosinusitis. Moreover, they acquire the status of the agents of choice for the therapy of chronic RS without polyps. Mometasone furoate is one of the best explored preparations of this group of medicines. It is possessed of favourable pharmacodynamic and pharmacokinetic properties when prescribed for local application. The new mometasone furoate preparation in the form of an intranasal spray Dezrinit produced by "Teva" Ltd. was registered in the Russian Federation. In a comparative randomized clinical trial (RCT), the preparation was shown to be an equivalent to the Nasonex spray